Other analysts also recently issued research reports about the stock. BTIG Research reaffirmed a buy rating and issued a $460.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, March 20th. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $416.00 target price on the stock in a report on Thursday, April 27th. Vetr downgraded shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $408.86 target price on the stock. in a report on Monday, April 24th. Piper Jaffray Companies set a $446.00 target price on shares of Regeneron Pharmaceuticals and gave the company a buy rating in a report on Wednesday, March 8th. Finally, Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating and lifted their target price for the company from $375.00 to $484.00 in a report on Friday, May 5th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have given a buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of Hold and an average target price of $438.99.
Regeneron Pharmaceuticals (NASDAQ REGN) traded down 2.64% during midday trading on Thursday, reaching $512.64. 1,310,665 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $456.19 and its 200-day moving average price is $393.90. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $514.57. The company has a market capitalization of $54.12 billion, a PE ratio of 62.06 and a beta of 1.53. Regeneron Pharmaceuticals also was the target of some unusual options trading activity on Friday. Stock investors acquired 1,150 put options on the stock. This is an increase of approximately 496% compared to the average volume of 193 put options.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.57 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals will post $12.67 EPS for the current year.
In other news, major shareholder Sanofi acquired 136,050 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was acquired at an average price of $478.17 per share, with a total value of $65,055,028.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robert J. Terifay sold 21,147 shares of the business’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $468.19, for a total transaction of $9,900,813.93. Following the completion of the transaction, the executive vice president now directly owns 72,043 shares of the company’s stock, valued at approximately $33,729,812.17. The disclosure for this sale can be found here. In the last three months, insiders sold 49,821 shares of company stock valued at $23,253,312. Company insiders own 10.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Grandfield & Dodd LLC raised its position in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 17 shares in the last quarter. Opus Point Partners Management LLC raised its position in Regeneron Pharmaceuticals by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 7,684 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 172 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $323,000. Princeton Capital Management Inc. raised its position in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 157 shares in the last quarter. Finally, CIBC World Markets Inc. raised its position in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock worth $8,442,000 after buying an additional 20,833 shares in the last quarter. 67.23% of the stock is owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/regeneron-pharmaceuticals-regn-outperform-rating-reaffirmed-at-leerink-swann/1934926.html
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.